United States Pharmaceuticals Market Is Estimated To Witness High Growth Owing To Opportunity Of Increased R&D Investment

 The United States pharmaceuticals market comprises drugs intended for human use only. Pharmaceutical drugs are classified as prescription-only medicines or over-the-counter medicines and are also categorized based on therapeutic application such as cardiovascular disorders, pain management, diabetes, cancer, infectious diseases, and respiratory diseases. Rising chronic disease prevalence coupled with increasing healthcare spending are the major drivers of the US pharmaceuticals market.

The United States pharmaceuticals Market was valued at US$ 599.47 Bn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023-2030, as highlighted in a new report published by CoherentMI.

Market Opportunity:

The opportunity of increased research and development (R&D) investment in the United States pharmaceuticals market is estimated to witness high growth. Pharmaceutical R&D plays a significant role in new drug development and the annual expenditure on pharmaceutical R&D witnessed significant growth over the past few years. However, the US lost its position as a global leader in pharmaceutical innovation due to insufficient funding for biomedical research over the past few years. The government needs to focus on increasing funding for biomedical research through the National Institutes of Health (NIH) and other funding programs, in order to tackle the rising disease burden. Increased R&D investment would help accelerate clinical research and drug discovery, allowing companies to launch novel drugs to treat chronic and complex diseases. This would augment the market growth of the US pharmaceuticals market over the forecast period.

Porter's Analysis

Threat of new entrants: The stringent regulations from FDA for drug approval acts as a major barrier for new entrants. Significant capital is required for R&D, clinical trials, manufacturing etc.

Bargaining power of buyers: Large pharmacy chains and hospitals have a strong bargaining power due to their high volume purchase. They negotiate on pricing and discounts to reduce costs.

Bargaining power of suppliers: Key raw material suppliers face less threat due to inelastic demand from pharma companies and differentiated products. Suppliers can bargain on pricing based on long term supply relationships.

Threat of new substitutes: Biologics have emerged as potential substitute for many drugs but require specialized manufacturing and administration process. Generic drugs post patent expiry become substitutes.

Competitive rivalry: The market is dominated by few large players who compete intensely on the basis of new product development, marketing, and patents.

SWOT Analysis

Strengths: Strong R&D capabilities, diversified product portfolio, global sales network, brand recognition.

Weaknesses: High dependence on blockbuster drugs, patent cliffs, pricing pressures, generics competition.

Opportunities: Rapid growth in biologics, rising healthcare expenditure, increased access to insurance, demand for specialty drugs.

Threats: Stringent regulatory approvals, drug price control policies, rising development & production costs.

United States Pharmaceuticals Market Segmentation

By Product Type

• Prescription Drugs
• Generic Drugs
• OTC Drugs
• Biologics
• Biosimilars

By Therapy Area

• Oncology
• Diabetes
• Autoimmune Diseases
• Neurological Disorders
• Cardiovascular
• Infectious Diseases
• Others (Respiratory, Gastrointestinal, etc.)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By End-User

• Hospitals
• Clinics
• Homecare
• Others

Key Takeaways

The  United States Pharmaceuticals Market Size is expected to witness high growth during the forecast period supported by rising healthcare spending, growing chronic disease burden and demand for innovative drugs. The market size is projected to reach US$ 899.24 Bn by 2030 from US$ 599.47 Bn in 2023, registering a CAGR of 8.6%.

The Western region dominates the market currently owing to presence of major pharmaceutical companies, high healthcare expenditure and high adoption rates of new drugs. However, the Southern states are expected to be the fastest growing region backed by increasing patient population, infrastructure investments and expansion initiatives by key players.

Key players operating in the United States pharmaceuticals market are Johnson & Johnson, Pfizer, AbbVie, Merck, Bristol-Myers Squibb, Amgen, Eli Lilly and Novartis. These companies have strong focus on developing specialized drugs for oncology, immunology and neurology through investments in R&D.

FAQ's

• What are the main factors influencing the United States pharmaceuticals Market?
• Which companies are the major sources in this industry?
• What are the market's opportunities, risks, and general structure?
• Which of the top United States pharmaceuticals Market   companies compare in terms of sales, revenue, and prices?

Explorer more information on this topic, Please visit @ https://www.marketwebjournal.com/united-states-pharmaceuticals-market-size-and-share-analysis/